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Abstract
Background: The majority of retirement village residents are at risk of medication misadventure. In a recent survey
of retirement village residents in Victoria, two-thirds had at least one medication-related risk factor, and hence were
eligible to receive a government-subsidised Home Medicines Review (HMR). However, only 6% of eligible residents
had received a HMR in the previous 12 months. Reasons for the poor uptake of HMR, and interventions for
improving HMR uptake, have been identified and developed with input from stakeholders. The trial will test the
effect of Pharmacist-conducted HMR to Address the Risk of Medication-related Events in Retirement Villages
(PHARMER) in improving the uptake of HMRs among retirement village residents.
Methods/Design: This is a multicentre prospective cluster randomised controlled trial. Ten retirement villages in
Victoria, Australia will be recruited for this trial. Retirement villages will be selected in consultation with the
Residents of Retirement Villages Victoria Inc. (RRVV), based on geographical locations (e.g. northeast or
southwest), size and other factors. Residents from selected villages will be recruited with the help of RRVV
Resident Liaison Officers using a range of strategies. Randomisation will be by geographical location to
minimise contamination. Participating villages and residents will be allocated to either Pharmacist Intervention
Group (PIG) or Usual Care Group (UCG). Each group will include five retirement villages and will have at least 77
residents in total. The intervention (PHARMER) comprises educating residents regarding HMR, and using a risk
assessment checklist by residents to notify their General Practitioners of their medication risk. Uptake of HMR
and medication adherence will be assessed in both PIG and UCG at three and six months using telephone
interviews and questionnaires.
Discussion: This study is the first to develop and test an intervention to improve the uptake of HMR among
Australian residents in retirement villages, with a view to decreasing medication risk. A multi-faceted interventional
approach will be used as suggested by stakeholders. The trial is expected to be complete by late 2011 and results
will be available in 2012.
Trial Registration: Australian New Zealand Clinical Trials Registry (ACTRN12611000109909)
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Retirement villages offer accommodation for older peo-
ple who wish to live independently or with limited assis-
tance within a supportive community. There are
approximately 1,756 retirement villages in Australia,
which accommodate approximately 80,000 residents
[1,2]. The number of residents in retirement villages is
projected to increase to 300,000 by 2051 [2].
The majority of residents living in retirement villages
are at risk of medication misadventure. In our recent
survey of 2,116 retirement village residents in Australia,
47% were using multiple medications, and 65% had one
or more medication-related risk factors, such as pre-
sence of three or more health conditions, use of five or
more medications, use of 12 or more medication doses
a day, use of medications with narrow therapeutic index
or recent changes to their medication regimen [3]. On
average, residents in the survey were using four medica-
tions [3]. A previous study found that 41% of retirement
village residents were using multiple medications includ-
ing potentially inappropriate combinations, confirming
that residents in retirement villages are at risk of medi-
cation misadventure [4].
The Australian Pharmaceutical Advisory Council, the
National Prescribing Service and the Pharmacy Guild of
Australia currently recommend medication reviews to
be conducted annually for people who are at risk of
medication misadventure [5-7]. Home Medicines Review
(HMR) is a government-subsidised medication manage-
ment review service that aims to optimise medication
use and health outcomes for individual patients living in
the community [8]. There is no charge to the patient,
and both general practitioners (GPs) and pharmacists
are reimbursed by Commonwealth Government for pro-
viding HMR [8]. HMR is a GP-initiated service con-
ducted by a pharmacist who is accredited to undertake
medication reviews.
The 65% of residents who had at least one medica-
tion-related risk factor in our survey would meet the
eligibility criteria for a HMR [3]; however, only 6% of
these at-risk residents had received a pharmacist-con-
ducted HMR in the previous 12 months, despite the
fact that the majority (94%) had regular visits to their
GPs [3].
The reasons for the poor uptake of HMR among
retirement village residents have been investigated by
our team, and interventions for increasing the uptake of
HMR in this group have been developed with input
from stakeholders including retirement village residents,
medical, pharmacy and allied health professionals [9]. A
multi-faceted interventional approach targeting residents
and their health professionals, such as educating resi-
dents regarding their risk factors and benefits of HMR,
and notifying GPs of residents at risk of medication mis-
adventure using a risk assessment checklist, have been
recommended by stakeholders to increase the uptake of
HMR in retirement village residents [9].
The Pharmacist-conducted HMR to Address the Risk
of Medication-related Events in Retirement Villages
(PHARMER) trial aims to test the effectiveness of a new
multi-component intervention delivered by a pharmacist
to increase the uptake of HMR among retirement village
residents (primary aim), and to improve residents’
adherence to medications (secondary aim). The hypoth-
esis is that residents receiving the intervention are more
likely to receive a HMR compared to their counterparts
receiving usual care, leading to higher HMR uptake at
three and six months from baseline.
Methods/Design
Study design
The PHARMER trial is a multi-centre prospective clus-
ter randomised controlled trial (RCT).
Study setting
Ten retirement villages within Victoria, Australia will be
recruited for this trial.
Identification and selection of retirement villages
Retirement villages eligible for the study, such as those
with a representative officer (also known as Resident
Liaison Officer [RLO]) from the Residents of Retirement
Villages Victoria Inc. (RRVV) [10], will be identified in
consultation with an officer of the RRVV. Eligible retire-
ment villages meeting the study criteria will be identified
by RRVV from their member database. Using the list
provided by RRVV, a convenience sample of ten retire-
ment villages will be selected for the study based on the
following factors:
￿ having at least 100 units;
￿ having at least 20 residents who are members of
RRVV; and
￿ geographical location (northeast and southwest
regions).
The two geographical locations will be used to avoid
potential contamination (see cluster randomisation).
The geographical locations (northeast or southwest) will
be randomised to intervention group (Pharmacist Inter-
vention Group [PIG]) or control group (Usual Care
Group [UCG]). Each group will include five retirement
villages and will have at least 15 km between the PIG
and UCG retirement villages. Selected villages should
have at least 20 RRVV members to enhance recruitment
of participants.
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The RLOs of selected retirement villages will be asked
to assist in recruiting their village for the study by facili-
tating the investigators’ approach to each village man-
ager for permission to carry out the study in their
village. If a selected village’s RLO is unable to assist,
another retirement village will be selected and its RLO
will be approached. This process will continue until 10
RLOs and their retirement villages are recruited for the
trial. Written permission will be obtained from each vil-
lage manager at the time of recruitment of each village.
Cluster randomisation
Randomisation to either PIG or UCG according to geo-
graphical location (northeast or southwest) will be car-
ried out by an independent person, using a simple
randomisation technique (e.g. pick of an envelope) at
the completion of retirement village recruitment. Rando-
misation by geographical locations of facility rather than
individual residents or individual retirement villages will
be used to minimise any potential contamination from
sharing of information between residents belonging to
different study groups, or from the same health profes-
sionals being involved in the care of residents from both
groups.
Recruitment of participants
Participants will be residents living in participating
retirement villages, recruited with the help of RLOs and
village managers. Residents will be recruited using a
range of strategies, which include:
￿ distributing invitation forms to all residents in each
village;
￿ displaying a poster on the notice board or in the
common area of each village; and
￿ advertising the study in the villages’ newsletters
and/or on the villages’ multi-screen televisions
(where available).
Residents who are interested in the study will be asked
to complete the invitation form and return it to the
study investigators using a provided reply-paid envelope,
or to contact the study investigators. The invitation
form includes questions that ask for the resident’sn a m e
and contact details, and assess their eligibility for partici-
pating in the study. Returned invitation forms will be
used to identify and select residents who are eligible for
the study. Eligible residents will be invited to participate
in the study over telephone. Those who are interested in
participating after this initial discussion will be sent a
plain language statement, a consent form and a ques-
tionnaire. They will be asked to complete the consent
form and questionnaire, and return them to the
investigators. Once written consent is obtained, eligible
residents will be enrolled in the trial and allocated to
either PIG or UCG depending on the location of the
retirement village they live in.
Inclusion criteria
Residents who meet the following criteria will be eligible
to participate in the study:
￿ living in one of the participating retirement
villages;
￿ aged 55 years and above;
￿ using three or more prescribed medications;
￿ expecting to visit their GP in the next three
months;
￿ expecting to be available for follow-up for at least
six months from baseline; and
￿ available to attend an education session.
Exclusion criteria
Residents will be ineligible to participate in the study if
they have any of the following characteristics:
￿ received a HMR in the previous 12 months;
￿ planning to move from their current retirement
village in the next six months;
￿ unable to give written informed consent; or
￿ unable to communicate in English.
The aim of the PHARMER trial is to target residents
who have not received a HMR in the previous 12
months and improve their uptake of HMR using educa-
tional interventions. Those who have had a HMR
experience in the previous 12 months are less likely to
receive any additional benefits from the educational
interventions because they are already aware of the ben-
efits of HMR; and they are also less likely to receive
another HMR referral from their GPs in the next 12
months, unless their condition changes (e.g. a recent
hospitalisation) and requires more frequent review.
Sample size
The sample size required for this study was calculated
based on the HMR uptake in the previous 12 months
(6%) reported in our recent survey [3]. From this figure,
we anticipate the uptake of HMR in the UCG to be 6%
after 12 months, 3% after 6 months and 1.5% after three
months. To demonstrate that the intervention increases
t h eu p t a k eo fH M R sf r o m3 %( i nt h eU C G )t o2 0 %( i n
the PIG) at six months (considered to be a relatively
conservative but clinically meaningful increase), with
80% power and a two-sided alpha value of 0.05, 55 par-
ticipants will be required in each group (total of 110
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low-up, and 20% for clustering effects, at least 77 parti-
cipants will be recruited into each arm at baseline (total
of at least 154 participants).
Interventions in the Pharmacist Intervention Group (PIG)
At baseline, participants in the PIG will receive the
intervention. The intervention to be tested includes sev-
eral components:
a. HMR education session
￿ A pharmacist, who is accredited to undertake
HMRs, will visit the PIG participants at their vil-
lages to deliver a group education session about
the role of and benefits from HMR. Information
leaflets about HMR will be given out to partici-
pants during these education sessions.
b. Medication risk assessment
￿ A medication risk assessment checklist will be
adapted from a screening tool that was pre-
viously developed and published by the Phar-
macy Guild of Australia (see Additional file 1:
Pharmacy Guild of Australia’s HMR consumer
brochure). The HMR consumer brochure
includes a self-administered checklist (with tick
boxes) consisting of 16 items assessing a person’s
risk factors for medication-related problems (e.g.
having recent hospitalisation, using multiple
medicines, having recent changes to medication
regimen, and using low therapeutic index medi-
cines). The checklist will be completed by parti-
cipants after the education session, with the
pharmacist taking them through each question.
The completed checklist will be used by the
pharmacist to identify participants who have
medication risk factors and thus could potentially
benefit from a HMR.
c. New referral process for HMR
￿ Participants identified as having one or more
medication risk factors will be referred to their
GP. Referral will be made by asking the at-risk
participant to give the completed medication risk
checklist to their GP during their next GP visit
and discuss the need for a HMR.
The group education session, including completion of
the medication risk checklist, will take approximately
one and a half hours.
Routine care in the Usual Care Group (UCG)
Participants enrolled in the UCG will continue to
receive routine care for six months during the study. No
intervention will be offered to this group at any time
during the study; however, they will not be denied a
HMR if they are being offered this in the course of
study as part of routine care. To ensure equity in both
PIG and UCG and to avoid unfair disadvantage to any
group, UCG participants will be offered a similar inter-
vention to the PIG after the study period (e.g. at six
months).
Outcome measures and data collection
Outcome measures
The primary outcome measure will be participants’
uptake of HMR; and secondary outcome measure will
be participant self-reported medication adherence. HMR
uptake will be assessed at three and six months from
baseline, and medication adherence at six months.
Baseline data collection
The baseline characteristics of participants will be col-
lected using a self-completed questionnaire. At baseline,
the questionnaire will be sent to participants with the
plain language statement and consent form. Information
collected by the baseline questionnaire includes:
￿ demographics;
￿ medication use data, including medication manage-
ment and problems experienced with medications;
￿ medication adherence [11];
￿ health-related quality of life [12]; and
￿ medication-related risk factors and eligibility for
HMR (see Additional file 1: Pharmacy Guild of Aus-
tralia’s HMR consumer brochure).
Participants’ medication adherence will be assessed
using the self-reported Morisky scale [11]. The Morisky
scale comprises four validated items, with responses to
each item scored 0 for ‘yes’ and 1 for ‘no’ (except for
the item ‘Are you always careful in taking your medi-
cines?’ where the score is reversed). The total score on
the Morisky scale ranges between 0 and 4; a score of
less than 4 represents nonadherence.
Participants’ health-related quality of life will be
assessed using the self-reported Short Form (SF)-12
®
Health Survey [12]. The SF-12
® Health Survey consists
of 12 validated items relating to physical and mental
health function. Responses to the items will be scored
and computed using an online scoring program [13].
The scoring method will give two sets of results - Phy-
sical Component Summary (PCS) and Mental Compo-
nent Summary (MCS) scores, with the scores ranging
f r o m0t o1 0 0 ,z e r or e p r e s e n t i n gt h el o w e s tl e v e lo f
health and 100 representing the highest level of health
[14].
Participants in both groups will be assessed for their
medication-related risk factors and eligibility for receiv-
ing a HMR using the criteria or items in the Pharmacy
Guild of Australia’s HMR consumer brochure (see
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these criteria will be considered eligible for a HMR.
Participants will be contacted by telephone to obtain
incomplete or missing responses.
Three-month follow up
At three months from baseline, participants in both the
PIG and the UCG will be interviewed by telephone to
assess their HMR uptake. In addition, participants in the
PIG will also be assessed for their experience of the
pharmacist-education session about the HMR service.
Participants’ uptake of HMR will be measured as the
proportion of participants who have had at least one
HMR since baseline.
Six-month follow up
At six months from baseline, measures of uptake of
HMR will be repeated in participants who have not
received a HMR at three months. To ensure reliability,
participant self-reported uptake of HMR will be verified
with their GP, community pharmacist and/or the phar-
macist who undertook the HMR, where possible. The
HMR uptake at six months from baseline will be com-
pared between the two study groups.
Participants in both groups will also be asked to com-
plete a questionnaire. Information collected at the six-
month follow up will include:
￿ any changes to medication regimens, including
problems experienced with use of medications since
baseline;
￿ medication adherence [11]; and
￿ health-related quality of life [12].
Data at three and six months will be collected by an
independent person who will be blinded to the group
allocation.
Data analysis
All data will be analysed according to intention-to-treat
principles. The baseline characteristics of participants in
the PIG and UCG will be compared using Chi-square,
Mann-Whitney U or Student t-test. Uptake of HMR in
the two study groups at three and six months will be
compared using Chi-square test. Paired samples t-test or
Wilcoxon Signed-Rank test will be used to compare
changes in Morisky scores and SF-12
® Health Survey
scores between the two groups at six months.
Ethics
This study has been approved by the Monash University
Human Research Ethics Committee. Written informed
consent will be obtained from all RLOs and participants
at the time of enrolment.
Study timeline
Ethics approval: December 2010
Trial commencement: January 2011 (recruitment of
RLOs and retirement villages)
Recruitment of participants and baseline data collec-
tion: February - March 2011
Implementation of interventions: April - June 2011
Three-month follow up: September 2011
Six-month follow up: December 2011
Data analysis: January - February 2012
Discussion
To our knowledge this will be the first study to
develop and test an intervention to improve the
uptake of medication review services by retirement vil-
lage residents in Australia, with a view to decreasing
medication risk. Most previous research on medication
review uptake has focused on the general populations
living in the community or war veterans [15-17]. We
will use a multi-faceted interventional approach target-
ing residents and their health professionals for increas-
ing the uptake of HMR, as suggested by stakeholders.
The effectiveness of such interventions (patient educa-
tion and GP feedback) in increasing the uptake of
HMRs has been well-established [16,18]. Our study is
endorsed and supported by RRVV and the Council on
the Ageing Victoria (COTA). Such collaborations with
RRVV and COTA, including the input from RLOs,
will facilitate the recruitment and conduct of this
study.
Additional material
Additional file 1: Pharmacy Guild of Australia’s HMR consumer
brochure (PDF).
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